DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20213739

Sustained viral remission with directly acting antivirals in the treatment of chronic hepatitis C among adolescent (12-17 years) survivors of childhood leukemia

Prasanth Kunjan Nadar Sobhan, Bindu Sarojam

Abstract


Studies from India highlight the high prevalence of hepatitis C (6-25%) infection in survivors of childhood cancers. Recently Directly acting antivirals (DAA) have been approved for treatment of Chronic hepatitis C (CHC) in children >12 years of age. Even though there are reports of efficacy and safety of DAAs in the treatment of CHC in hematologic disorders like thalassemia, there is minimal data on the efficacy of DAA in the management of chronic hepatitis C among adolescent survivors of childhood leukaemia. We performed this retrospective analysis to study Sustained viral remission (SVR) with DAA in the treatment of CHC among adolescent (12-17 years) survivors of childhood leukemia. This study also aimed to analyze the genotypic profile of hepatitis C virus and adverse effects of the DAA in this group of adolescents (12-17 years). 5 adolescents (12-17 years) who were diagnosed with CHC during August 2017 to May 2020 were enrolled in this observational study. All belonged to genotype 1; received DAA regimen comprising of sofosbuvir 400 mg and ledipasvir 90 mg for 12 weeks with good drug compliance and no major adverse effects. All of them attained SVR at 12 weeks after completing treatment. This study among adolescent survivors of childhood leukaemia with chronic hepatitis C genotype 1, augments data regarding efficacy of a 12 weeks DAA regimen comprising of sofosbuvir 400 mg and ledipasvir 90 mg in the attainment of SVR at 12 weeks after completing treatment.


Keywords


Chronic hepatitis C, DAA, SVR

Full Text:

PDF

References


Indolfi G, Easterbrook P, Dusheiko G, Sayed MH, Jonas MM, Thorne C, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):477-87.

Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, Paola M, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol. 2020;5(4):374-92.

Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):505-15.

Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major. J Clin Exp Hepatol. 2017;7(3):172-8.

Kurkure P, Achrekar S, Dalvi N, Goswami S. Childhood cancer survivors—living beyond cure. Indian J Pediatr. 2003;70:825-8.

Rajendranath R, Veeraiah S, Ramesh A, Sagar TG. Late effects of treatment in survivors of childhood cancer from a tertiary cancer center in South India. South Asian J Cancer. 2014;3(1):60-5.

Seth R, Singh A, Guru V, Chawla B, Pathy S, Sapra S. Long-term follow-up of retinoblastoma survivors: Experience from India. South Asian J Cancer. 2017;6(4):176-9.

Nagral A, Jhaveri A, Sawant S, Parikh NS, Nagral N, Merchant R, et al. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major. Indian J Pediatr. 2019;86(2):148-53.

Dhiman RK, Grover GS, Premkumar M, Taneja S, Duseja A, Rathi S, et al. Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: J Pediatr Gastroenterol Nutr. 2019;68(1):74-80.

Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. J Pediatr Hematol Oncol. 2018;40(7):511-4.

Sivasankaran M, Venkatadesikalu M, Mythili V, Sankaranarayanan S, Jayaraman D, Patel S, et al. Ushering a New Era in the Management of Hepatitis C in Children with Hematological Disorders. Indian J Hematol Blood Transfus. 2018; 34(4):739-41.